Latest Commercialization News

Race Oncology has filed pivotal patents on the active (E,E)-bisantrene isomer, potentially extending its drug exclusivity by two decades, while advancing its Phase 1 clinical trial and maintaining a strong cash position.

PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.

Pathkey.AI reports strong validation of its TrialKey AI platform’s predictive accuracy and announces key leadership changes as it advances toward commercial scale.

Mach7 Technologies reports a modest rise in recurring revenue alongside a comprehensive commercial transformation, positioning itself for growth in AI-driven medical imaging.

Top End Energy has unveiled a significant prospective hydrogen resource in Kansas and strengthened its U.S. market presence with new OTCQB listings, while advancing strategic discussions in Australia’s Beetaloo Basin.

Mach7 Technologies reports a pivotal first quarter for FY26, marked by the initial go-live of a major U.S. Veterans Health Administration contract, leadership changes, and a strategic business reset.

Rimfire Pacific Mining is set to begin an 85-hole infill drilling program at its Murga Exploration Target, aiming to convert it into a mineral resource by early 2026 and significantly expand its scandium inventory.

Zoono Group Limited reports strong progress in its shelf-life extension technology with 50 active trials worldwide and anticipates its first significant sales this quarter, supported by fresh funding and expanding market interest.

Hastings Technology Metals has completed a transformative joint venture with Wyloo for its Yangibana Rare Earths Project, eliminating $123 million in debt and divesting its gold portfolio to sharpen its rare earths focus.

Audio Pixels Holdings has made significant technical strides in its MEMS-based Digital Sound Reconstruction technology while securing $1.25 million in new convertible note funding. Despite progress, the company remains suspended from ASX pending further capital raises.

WA Kaolin Limited has reported a remarkable surge in sales volumes and revenue for the September 2025 quarter, driven by operational upgrades and expanding market reach. The company’s forward orders and product diversification signal robust growth ahead.

Nova Eye Medical reported a robust 32% increase in global sales excluding China for Q1 FY26 and secured regulatory approval for its iTrack™ Advance device in China, setting the stage for expanded market penetration.